We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CLAR:NASDAQClarus Corporation Analysis

Data as of 2026-08-26 - not real-time

$3.80

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Clarus Corporation is priced at $3.80 and its moving averages line up in bullish order, the shorter sitting above the longer. Across the trailing 30 sessions it gained 16.6%. Relative strength is 63.2 — approaching overbought — and the MACD signal is bullish. Price has been bracketed by support at $3.16 and resistance at $3.98.
Valuation screens as fair, on a P/E of 21.9 with no clean sector comparison available. Sell-side targets cluster 5.1% below the current quote. The 2.62% dividend yield looks covered by current payout levels.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 42.2%, a beta of 1.09 and a maximum drawdown of 36.8%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 1/10 conviction over the longer horizon.

Top Market Events

Outdoor lifestyle and equipment company Clarus NASDAQ:CLAR reported Q2 CY2026 results , with sales up 1.SALT LAKE CITY, Aug. 05, 2026 GLOBE NEWSWIRE -- Clarus Corporation NASDAQ: CLAR “Clarus” and/or the “Company” ,...Clarus Reports Second Quarter 2026 Results.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 3.22
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 3.22
  • Analyst targets imply -5.1% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Negative profit margin of -12.4%
  • Analyst targets imply -5.1% versus the current price
  • Negative return on equity of -14.9%

Key Metrics & Analysis

Financial Health

Revenue Growth1.60%
Profit Margin-12.44%
P/E Ratio21.9
ROE-14.87%
ROA-2.23%
Debt/Equity8.66
P/B Ratio0.7
Op. Cash Flow$4.4M
Free Cash Flow$11.7M

Technical Analysis

TrendBullish
RSI63.2
Support$3.16
Resistance$3.98
MA 20$3.57
MA 50$3.37
MA 200$3.22
MACDBullish
VolumeIncreasing
Fear & Greed Index93.84

Valuation

Fair Value$4.49
Target Price$3.61
Upside/Downside-5.11%
GradeFair
TypeValue
Dividend Yield2.62%

Risk Assessment

Beta1.09
Volatility42.16%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.